LONDON (Alliance News) - ANGLE PLC said Monday it appointed urological surgeon, Greg Shaw, as a scientific advisor.
The liquid biopsy company appointed the prostate cancer UK National Health Service surgeon to its scientific advisory board.
Shaw is currently a consultant urological surgeon at University College Hospital in London and a honorary senior lecturer at University College and Queen Mary College of the University of London.
ANGLE Founder & Chief Executive Officer Andrew Newland said: "Greg's understanding of current clinical practice in the UK and the key areas of medical need that liquid biopsy can address will help us to position ParsortixTM clinical applications for prostate cancer in the future."
Shares in ANGLE were trading 0.1% higher at 43.95 pence.
Angle (AGL)